title: Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
authors.affiliation: zracil@fnbrno.cz.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Racil
authors.forename: Filip
authors.initials: F
authors.lastname: Razga
authors.forename: Jana
authors.initials: J
authors.lastname: Drapalova
authors.forename: Lucie
authors.initials: L
authors.lastname: Buresova
authors.forename: Daniela
authors.initials: D
authors.lastname: Zackova
authors.forename: Martina
authors.initials: M
authors.lastname: Palackova
authors.forename: Lukas
authors.initials: L
authors.lastname: Semerad
authors.forename: Ludmila
authors.initials: L
authors.lastname: Malaskova
authors.forename: Martin
authors.initials: M
authors.lastname: Haluzik
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism*; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D001786:Blood Glucose; D011743:Pyrimidines; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D005947:Glucose
keywords: glucose metabolism; nilotinib; tyrosin kinase inhibitor